Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GE HealthCare Technologies (GEHC) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for GE HealthCare Technologies (GEHC) over the last 4 years, with Q4 2025 value amounting to $2.6 billion.

  • GE HealthCare Technologies' Cost of Revenue rose 1455.53% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.9 billion, marking a year-over-year increase of 812.48%. This contributed to the annual value of $8.9 billion for FY2025, which is 811.27% up from last year.
  • Per GE HealthCare Technologies' latest filing, its Cost of Revenue stood at $2.6 billion for Q4 2025, which was up 1455.53% from $2.3 billion recorded in Q3 2025.
  • GE HealthCare Technologies' Cost of Revenue's 5-year high stood at $2.6 billion during Q4 2025, with a 5-year trough of $1.9 billion in Q1 2022.
  • For the 4-year period, GE HealthCare Technologies' Cost of Revenue averaged around $2.1 billion, with its median value being $2.1 billion (2023).
  • In the last 5 years, GE HealthCare Technologies' Cost of Revenue tumbled by 343.64% in 2024 and then soared by 1455.53% in 2025.
  • Over the past 4 years, GE HealthCare Technologies' Cost of Revenue (Quarter) stood at $2.2 billion in 2022, then grew by 5.49% to $2.3 billion in 2023, then decreased by 1.85% to $2.2 billion in 2024, then increased by 14.56% to $2.6 billion in 2025.
  • Its Cost of Revenue stands at $2.6 billion for Q4 2025, versus $2.3 billion for Q3 2025 and $2.2 billion for Q2 2025.